Estimates in bold reflect a risk/ratio statistically significantly different from 1, ie association is statistically significant.
More details are found in online supplementary tables S32–S38.
*Milan refers the Milan Cancer Report and Varese to the Varese Cancer Registry database. These were the general population comparators used.
†Standardised incidence rates are reported, with the general population as the reference; SIR of 100 means no difference between incidence rates.
‡n=2 cases.
ABA, abatacept; ADA, adalimumab; aHR, adjusted HR; ANA, anakinra; ARTIS, Swedish Biologics Register; BCC, basal cell carcinoma; bDMARDs, biological disease-modifying antirheumatic drugs; BIOBADASER, Spanish Biologics Register; BSRBR, British Society of Rheumatology Biologics Register; CORRONA, Consortium of Rheumatology Researchers of North America; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; ETA, etanercept; IFX, infliximab; LOHREN, Lombardy Rheumatology Network (Italian Biologics Register); MTX, methotrexate; NA, not available (not mentioned in the original article); NR, not reported; pts, patients; RABBIT, Rheumatoid Arthritis Observation of Biologic Therapy ( in German); RATIO, French Biologics Register; RTX, rituximab; SCC, squamous cell carcinoma; TNFi, tumour necrosis factor α inhibitor.